Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title: Real-world Study of Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma

Status Active, not recruiting

Clinical Trial Summary

Study purpose: To evaluate the efficacy and safety of Tislelizumab in combination with advanced hepatocellular carcinoma in the real world; Study design: Non-intervention, single center, case registration, real-world study; Number of registrations: 40;

Source of data: This project is a non-interventionary real world case follow-up registration. All registration data are from real clinical practice cases. The collected data include the following requirements:

1. Age ≥18 years old;

2. Unresectable hepatocellular carcinoma confirmed by histological examination or clinical diagnosis;

3. Plan or have received systemic therapy combined with Tiralizumab;

4. No participation in other clinical studies;

5. Access to Tislelizumab treatment and other clinical records; Primary endpoint: Overall response rate; Secondary endpoint: Disease control rate, progress free survival, overall survival, safety; Exploratory endpoint: To explore the predictive value of multiple Biomarker combinations, such as PD-L1, TMB, MSI, DDR, POLE/POLD, in HCC immunotherapy response.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

• NCT number: NCT04996459
• Study type: Observational [Patient Registry]
• Source: Fudan University
• Status: Active, not recruiting
• Start date: March 1, 2020
• Completion date: June 2022